# Tabomedex Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tabomedex-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.tabomedex.com
- Total disclosed funding: $10M
- Latest round: Series A (Dec 29, 2017)
- Investors on record: 3

## About

Based in Massachusetts, US, Tabomedex Biosciences, Inc. is a biotechnology company that focuses on the R&D of new drugs for type 2 diabetes. The company's team member, Dr.Ira Tabas is a Professor of medicine and cell biology at Columbia University, and he discovered that hepatocyte signaling has revealed novel drug targets for type 2 diabetes. Dr.IRA TABAS also published over 200 papers in journals, such as  Cell, Nature, and Science. The company team member, Lale Ozcan, is an Assistant Professor in the Department of Medicine at Columbia University Medical Center and her work focuses on exploring novel signaling pathways that control metabolic homeostasis.

The company foucses on the R&D of new drugs related to type 2 diabetes. They study the mechanism of action of MK2 and achieve the effect of controlling blood glucose levels by inhibiting MK2. The company's research reports include that mouse studies point to kinase as a diabetes treatment target, and a new link between obesity and diabetes was found.

## Funding rounds

- Series A, Dec 29, 2017, $5M — Viva Ventures Biotech
- Series A, Apr 1, 2016, $5M — JMCR Family Office, Viva Ventures Biotech, Viva BioInnovator

## Investors

- JMCR Family Office — Series A
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series A
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A